|
Name |
Cristatumin D
|
Molecular Formula | C19H21N3O4 | |
IUPAC Name* |
methyl (Z)-3-[2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl]-2-(oxamoylamino)prop-2-enoate
|
|
SMILES |
CC(C)(C=C)C1=C(C2=CC=CC=C2N1)/C=C(/C(=O)OC)\NC(=O)C(=O)N
|
|
InChI |
InChI=1S/C19H21N3O4/c1-5-19(2,3)15-12(11-8-6-7-9-13(11)21-15)10-14(18(25)26-4)22-17(24)16(20)23/h5-10,21H,1H2,2-4H3,(H2,20,23)(H,22,24)/b14-10-
|
|
InChIKey |
WMAYXXXLOKRQKS-UVTDQMKNSA-N
|
|
Synonyms |
Cristatumin D; CHEMBL2048728
|
|
CAS | NA | |
PubChem CID | 70684150 | |
ChEMBL ID | CHEMBL2048728 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 355.4 | ALogp: | 3.0 |
HBD: | 3 | HBA: | 4 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 114.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 26 | QED Weighted: | 0.33 |
Caco-2 Permeability: | -4.881 | MDCK Permeability: | 0.00002240 |
Pgp-inhibitor: | 0.63 | Pgp-substrate: | 0.008 |
Human Intestinal Absorption (HIA): | 0.01 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.009 |
Blood-Brain-Barrier Penetration (BBB): | 0.55 | Plasma Protein Binding (PPB): | 90.33% |
Volume Distribution (VD): | 0.41 | Fu: | 4.49% |
CYP1A2-inhibitor: | 0.905 | CYP1A2-substrate: | 0.881 |
CYP2C19-inhibitor: | 0.774 | CYP2C19-substrate: | 0.103 |
CYP2C9-inhibitor: | 0.439 | CYP2C9-substrate: | 0.891 |
CYP2D6-inhibitor: | 0.218 | CYP2D6-substrate: | 0.744 |
CYP3A4-inhibitor: | 0.798 | CYP3A4-substrate: | 0.464 |
Clearance (CL): | 2.324 | Half-life (T1/2): | 0.525 |
hERG Blockers: | 0.016 | Human Hepatotoxicity (H-HT): | 0.323 |
Drug-inuced Liver Injury (DILI): | 0.947 | AMES Toxicity: | 0.164 |
Rat Oral Acute Toxicity: | 0.692 | Maximum Recommended Daily Dose: | 0.029 |
Skin Sensitization: | 0.282 | Carcinogencity: | 0.063 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.019 |
Respiratory Toxicity: | 0.969 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002214 | 0.541 | D0J1MI | 0.267 | ||||
ENC002459 | 0.454 | D0H5MB | 0.263 | ||||
ENC001957 | 0.447 | D04OSE | 0.257 | ||||
ENC005569 | 0.447 | D0W7WC | 0.254 | ||||
ENC004237 | 0.444 | D08GJO | 0.252 | ||||
ENC004232 | 0.439 | D0BV3J | 0.252 | ||||
ENC002717 | 0.438 | D01JGV | 0.250 | ||||
ENC002446 | 0.432 | D0U7GP | 0.250 | ||||
ENC004927 | 0.427 | D05QHL | 0.248 | ||||
ENC004234 | 0.424 | D07ONP | 0.247 |